Caveolin-1, breast cancer and ionizing radiation

Cancer Genomics and Proteomics

Volumn 12, Issue 3, 2015, Pages 143-152

  Pucci, Marzia ^a,e   Bravatà, Valentina ^a   Forte, Giusi Irma ^a   Cammarata, Francesco Paolo ^a   Messa, Cristina ^a,b,c   Gilardi, Maria Carla ^a,b,d   Minafra, Luigi ^a  

^a IBFM CNR LATO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Biomarker; Breast cancer; CAV1; Ionizing radiation; Review

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CAVEOLA; EPITHELIUM; HUMAN; IONIZING RADIATION; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PROTEIN FUNCTION; REVIEW; STROMA; TREATMENT RESPONSE; TUMOR CELL; TUMOR SUPPRESSOR GENE; ANIMAL; BREAST NEOPLASMS; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; RADIATION RESPONSE; RADIOTHERAPY;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CAVEOLIN 1; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; RADIATION, IONIZING; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84929666854     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Minafra L, Norata R, Bravatà V, Viola M, Lupo C, Gelfi C and Messa C: Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: a study report. BMC Res Notes 5: 343, 2012.
2. Bravatà V, Cammarata FP, Forte GI and Minafra L: "Omics" of HER2-positive breast cancer. OMICS 17(3): 119-29, 2013.
3. Minafra L, Bravatà V, Forte GI, Cammarata FP, Gilardi MC and Messa C: Gene-expression profiling of epithelial-mesenchymal transition in primary breast cancer cell culture. Anticancer Res 34: 2173-2184, 2014.
4. Bravatà V, Stefano A, Cammarata FP, Minafra L, Russo G, Nicolosi S, Pulizzi S, Gelfi C, Gilardi MC and Messa C: Genotyping analysis and 18F-FDG uptake in breast cancer patients: a preliminary research. J Exp Clin Cancer Res 32: 23, 2013.
5. American Cancer Society: Cancer Facts and Figures 2015. Atlanta, GA, American Cancer Society, 2015.
6. Yamashiro H, Toi M: Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 13: 3-7, 2008.
7. Mercier I, Jasmin JF, Pavlides S, Minetti C, Flomenberg N, Pestell RG, Frank PG, Sotgia F and Lisanti MP: Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest 89: 614-623, 2009.
8. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C and Lisanti MP: Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J Biol Chem 274: 25718-25, 1999.
9. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J and Fan Z: Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67(17): 8240-8247, 2007.
10. Razani B, Woodman SE and Lisanti MP: Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431-467, 2002.
11. Lisanti MP, Scherer P, Tang Z-L and Sargiacomo M: Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol 4: 231-235, 1994.
12. Williams TM and Lisanti MP: The Caveolin genes: from cell biology to medicine. Ann Med 36: 584-595, 2004.
13. Li L, Ren CH, Tahir SA, Ren C and Thompson TC: Caveolin-1 maintains activated AKT in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23: 9389-9404, 2003.
14. Hehlgans S and Cordes N: Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance. Am J Cancer Res 4: 521-530, 2011.
15. EngelmanJA, Zhang XL and Lisanti MP: Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436: 403-410, 1998.
16. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA and Lisanti MP: Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168: 1998-2013, 2006.
17. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T and Hamaguchi M: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001.
18. WitkiewiczA, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR and Lisanti MP: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174: 2023-2034, 2009.
19. El-Gendi SM, Mostafa MF and El-Gendi AM: Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res 18: 459-469, 2012.
20. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nature Rev Cancer 6: 392-401, 2006.
21. Tlsty TD and Hein PW: Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Gen Dev 11: 54-59, 2011.
22. Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M, Tsuyuki S, Inamoto T, Toi M.Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M, Tsuyuki S, Inamoto T and Toi M: Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 102: 1590-1596, 2011.
23. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE and Lisanti MP: Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 39: 13916-13924, 2000.
24. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG and Lisanti MP: Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for mammary tumorigenesis. J Biol Chem 273: 20448-20455, 1998.
25. Glait C, Ravid D, Lee SW, Liscovitch M and Werner H: Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells. FEBS Lett 580(22): 5268-5274, 2006.
26. Wang Y, Yu J and Zhan Q: BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness. Biochem Biophys Res Commun 370(2): 201-206, 2008.
27. Caselli A, Mazzinghi B, Camici G, Manao G and Ramponi G: Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. BiochemBiophys Res Commun 296(3): 692-697, 2002.
28. Liu P, Ying Y and Anderson RG: Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. Proc Natl Acad Sci USA 94: 13666-13670, 1997.
29. Smart EJ, Ying YS, Mineo C and Anderson RG: A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci USA 92: 10104-10108, 1995.
30. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS and Lisanti MP: Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 428: 205-211, 1998.
31. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM and Arnold A: A novel cyclin encoded by abcl1-linked candidate oncogene. Nature 350: 512-515, 1991.
32. Lew DJ, Dulic V and Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66: 1197-1206, 1991.
33. Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342, 1993.
34. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ and Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630, 1995.
35. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP and Pestell RG: The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 275: 21203-21209, 2000.
36. Volonte D, Galbiati F, Pestell RG and Lisanti MP: Cellular stress induces the tyrosinephosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J Biol Chem 276: 8094-8103, 2001.
37. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG and Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275: 20171-20725, 2000.
38. Zundel W, Swiersz LM and Giaccia A: Caveolin-1 mediated regulation of receptor tyrosine kinase-associated phosphatidyl-inositol 3-kinase activity by ceramide. Mol Cell Biol 20: 1507-1514, 2000.
39. Liu J, Lee P, Galbiati F, KitsisRN and Lisanti MP: Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol 280: C823-C835, 2001.
40. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG and Lisanti MP: Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of CAV1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279: 51630-51646, 2004.
41. Sloan EK, Stanley KL and Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897, 2004.
42. Coussens LM and Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol 3: 895-904, 1996.
43. Lacroix-Triki M, Geyer FC and Reis-Filho JS: Caveolin-1 P132L mutation in human cancers: 1CAVeat to be voiced. J MolDiagn 12(5): 562-5, 2010.
44. Hayashi K, Matsuda S, Machida K,Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T and Hamaguchi M: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001.
45. Lee H, Park DS, Razani B,Russell RG, Pestell RG and Lisanti MP: Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1(-/-)null mice show mammary epithelial cell hyperplasia. Am J Pathol 161: 1357-1369, 2002.
46. Mercier I, Bryant KG, Sotgia F,Bonuccelli G, Witkiewicz AK, Dasgupta A, Jasmin JF, Pestell RG and Lisanti MP: Using caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the caveolin-1 (P132L) mutation. Cell Cycle 8(9): 1396-1401, 2009.
47. Bonuccelli G, Casimiro MC, Sotgia F,Wang C, Liu M, Katiyar S, Zhou J, Dew E, Capozza F, Daumer KM, Minetti C, Milliman JN, Alpy F, Rio MC, Tomasetto C, Mercier I, Flomenberg N, Frank PG, Pestell RG and Lisanti MP: Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol 174: 1650-1662, 2009.
48. Shatz M and Liscovitch M: Caveolin-1: a tumor-promoting role in human cancer. Int J RadiatBiol 84(3): 177-189, 2008.
49. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, ItohT, Okushiba S, Kondo S and Katoh H: Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94(4): 929-933, 2002.
50. Martinez-Outschoorn UE, Lisanti MP and Sotgia F: Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth.Semin Cancer Biol 25: 47-60, 2014.
51. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrión FD, Gago FE and Anderson RL: Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 174: 2035-2043, 2009.
52. Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134, 2010.
53. Hubbard R and Miller WT: Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 117-123, 2007.
54. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, WindleJJ, Pestel RG and Lisanti MP: Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273(32): 20448-20455, 1998.
55. Sekhar SC, Kasai T, Satoh A, Shigehiro T, Mizutani A, Murakami H, El-Aarag BY, Salomon DS, Massaguer A, de Llorens R and Seno M: Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J Cancer 4(5): 391-401, 2013.
56. Hashizume T, Fukuda T, NagaokaT, Tada H, Yamada H, Watanabe K, Salomon DS, Seno M: Cell type-dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biol Int 32: 814-826, 2008.
57. Patani N, Martin LA, Reis-Filho JS, Dowsett M: The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat 131: 1-15, 2012.
58. von der Heyde S, Wagner S, Czerny A, Nietert M, Ludewig F, Salinas-Riester G, Arlt D, Beißbarth T :mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer. PLoS One 10(2): e0117818, 2015.
59. Wanner G, Mayer C, Kehlbach R, Rodemann HP, Dittman K: Activation of protein kinase Cå stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol 86(3): 383-390, 2008.
60. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG and Lisanti MP: Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 174(4): 1172-1190, 2009.
61. Ithana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y:Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 12: 1151-1164, 2003.
62. Babina IS, Donatello S, Nabi IR, Hopkins AM. Lipid rafts as master regulators of breast cancer cell function. In: Breast Cancer-Carcinogenesis, Cell Growth and Signalling Pathways. Editors: M. Gunduz, E. Gunduz. InTech (ISBN 978-953-307-714-7), 2011.
63. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV and Lisanti MP: Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 181(1): 278-293, 2012.
64. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F, Lisanti MP: The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 9(21): 4297-4306, 2010.
65. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB,Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F and Lisanti MP: Oxidative stress in cancer associated fibroblasts drives tumor-stroma coevolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9(16): 3256-3276, 2010.
66. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES and Lisanti MP: Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 down-regulation and RB tumor-suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther 7(8): 1212-1225, 2008.
67. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, Tanowitz HB, Casimiro MC, Wang C, Pestell RG, Grieshaber P, Caro J, Sotgia F and Lisanti MP: HIF1α functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 9: 3534-3551, 2010.
68. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, Howell A, Pestell RG, Lisanti MP and Sotgia F: Tumor cells induce the cancer-associated fibriblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9: 2423-2433, 2010.
69. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F and Lisanti MP: Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease and "Neuron-Glia Metabolic Coupling". Aging 2: 185-199, 2010.
70. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F and Lisanti MP: The Reverse Warburg effect: aerobic glycolysis in cancer-associated fibroblasts and the tumor stroma. Cell Cycle 8: 3984-4001, 2009.
71. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, .Pestell TG, Howell A, Sneddon S, Pestell RG, Martinez-Outschoorn U, Lisanti MP and Sotgia F: CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 11(12): 2272-84, 2012.
72. Chien W, O' Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM and Koeffler HP: Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 38: 1741-7, 2011.
73. Lai D, Ho KC, Hao Y and Yang X: Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets CYR61and CTGF. Cancer Res 71: 2728-2738, 2011.
74. Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT, Chang KJ and Kuo ML: Connective tissue growth factor confers drug resistance in breast cancer through concomitant up regulation of BCL-xL and CIAP1. Cancer Res 69: 3482-3491, 2009.
75. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of the CCN family members CYR61, CTGF and NOV in human breast cancer. Endocr Relat Cancer 11: 781-791, 2004.
76. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP: Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, withouth a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 9: 2412-2422, 2010.
77. Pennacchietti S, Micheli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene. Cancer Cell 3: 347-361, 2003.
78. Grepin R and Pages G: Molecular mechanisms of resistance to tumor anti-angiogenic strategies. J Oncol 2010: 835680, 2010.
79. West CM and Barnett GC: Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med 3(8): 52, 2011.
80. Di Maggio FM, Minafra L, Forte GI, Cammarata FP, Lio D, Messa C, Gilardi MC and Bravatà V: Portrait of inflammatory response to ionizing radiation treatment. J Inflamm 12: 14, 2015.
81. Hehlgans S, Eke I, Storch K, Haase M, Baretton GB and Cordes N: Caveolin-1-mediated radioresistance of 3D grown pancreatic cancer cells. Radiother Oncol 92(3): 362-370, 2009.
82. Cordes N, Frick S, Brunner TB, Pilarsky C, Grutzmann R, Sipos B, Kloppel G, McKenna WG and Bernahrd EJ: Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26: 6851-6862, 2007.
83. Zhu H, Yue J, Pan Z, Wu H, Cheng Y, Lu H, Ren X, Yao M, Shen Z and Yang JM: Involvment of caveolin-1 in repair of DNA Damage through both homologous recombination and non-homologous end joining. PLoSOne 5(8): e12055, 2010.
84. Minafra L and Bravatà V: Cell and molecular response to IORT treatment. Transl Cancer Res 3: 32-47, 2014.
85. Bravatà V, Minafra L, Russo G, Forte GI, Cammarata FP. Ripamonti M, Casarino, Augello G, Costantini F, Barbieri G, Messa C and Gilardi MC: High-dose ionizing radiation regulates gene expression changes in MCF7 breast cancer cell line. Anticancer Res 35: 5, 2015.
86. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, Barbieri V, Jank S, Doppler W, Rasse M and Norer B: High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncology 43(2): 193-198, 2007.
87. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R and Rodemann HP: Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280(35): 182-31189, 2005.
88. Yotsumoto F, Yagi H, Suzuki SO, Oki E, T sujoka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E and Miyamoto S: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365(3): 555-561, 2008.
89. Ferrer-Soler L, Vazquez-Martin A, Brunet L, Menenedez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa-induced changes in the expression and nucleocytoplasmic trafficking of HER-ligands. Int J Mal Med 20(1): 3-10, 2007.
90. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK and Chen PB: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15(10): 1191-1197, 1997.
91. Knebel A, Rahmsordf HJ, Ullrich A and Herrlich P: Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. Embo J 15(19): 5314-5325, 1996.
92. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L: Cross-talk between epidermal growth factor and hypoxia-inducible factor-I alpha signal pathways increases resistance to apoptosis by up-regulating surviving gene expression. J Biol Chem 281(36): 25903-25914, 2006.
93. Evodin AL, Guzhova IV, Margulis BA and Medvedeva ND: Extracellular heat shock protein 70 mediates heat stress-induced epidermal growth factor receptor transactivation in A431 carcinoma cells. FEBS Lett 580(28-29): 6674-6678, 2006.
94. Tanos B and Pendergast AM: Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 281(43): 32714-32723, 2006.
95. Bhola NE and Grandis JR: Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 13: 1857-1865, 2008.
96. Drube S, Stirnweiss J, Valkova C, Liebmann C: Ligand-independent and EGF receptor-supported transactivation: lessons from beta2-adrenergic receptor signaling. Cell Signal 18(10): 1633-1646, 2006.
97. Wang Q, Zhu F, Wang Z: Identification of EGF receptor C-terminal sequences 1005-1017 and di-leucine motif 1010LL1011 as essential in EGF receptor endocytosis. Exp Cell Res 313(15): 3349-3363, 2007.
98. Rodemann HP, Dittmann K, Toulany M: Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiation Biol 83(11): 781-791, 2007.
99. Saito T, Okada S, Ohshima K, Yamada E, Sato M, Uehara Y, Shimizu H, Pessin JE and Mori M: Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by β-cellulin and EGF. Endocrinology 145(9): 4232-4243, 2004.
100. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chwn J,K, Baumann M, Dikomey E and Rodemann HP: Blockage of epidermal growth factor receptor-phospatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS-mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12(13): 4119-4126, 2006.
101. Mills IG: The interplay between clathrin-coated vescicles and cell signaling. Semin Cell DevBiol 18(4): 459-470, 2007.
102. Kirkham M, Parton RG: Clathrin-independent endocytosis: new insight into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 1746(3): 349-363, 2005.
103. Khan EM, Heidinger JM, Levy M, Lisanti MP, Ravid T and Goldkorn T: Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking.J Biol Chem 281(20): 14486-14493, 2006.
104. Dittman K, Mayer C, Wanner G, Kehlbach R and Rodemann HP: The radioprotector O-phospho-tyrosine stimulates DNA-repair via epidermal growth factor receptor-and DNA-dependent kinase phosphorylation. Radiother Oncol 84(3): 328-334, 2007.
105. Dittmann K, Mayer C, Kehlbach R and Rodemann HP: Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 12;7: 69, 2008.
106. Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K and Schmidt-Ullrichr RK: Requirment of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J Biol Chem 280(15): 14597-14604, 2005.